B. Riley Securities Reiterates Buy Rating for Elicio Therapeutics
B. Riley Securities maintains its buy rating on Elicio Therapeutics with a $27 price target, a 561.76% upside from the current price.
Key Points
- B. Riley Securities reiterated its buy rating for Elicio Therapeutics on June 10, 2026, with a $27 price target.
- B. Riley Securities's $27 price target implies 561.76% upside from Elicio Therapeutics, Inc.'s ($ELTX) current $4.08 share price.
- Elicio Therapeutics, trading at $14.85, focuses on cancer immunotherapies and has a market cap of $283 million.
- Institutional investors like Renaissance Technologies and Vanguard Capital have adjusted their positions in ELTX.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
B. Riley Securities reiterated its buy rating for Elicio Therapeutics, Inc. (NasdaqCM: ELTX) on June 10, 2026, setting a price target of $27. Shares of Elicio are currently trading at $14.85. This update reflects the firm's confidence in the company's prospects.
Other Institutional Activity in Elicio Therapeutics
Several institutional investors have made recent moves in Elicio Therapeutics. Renaissance Technologies LLC significantly boosted its position by 93,520 shares, ending with 121,631 shares valued at approximately $1.3 million. Vanguard Capital Management LLC initiated a new position with 518,638 shares worth about $5.5 million. Meanwhile, Balyasny Asset Management L.P. increased its holdings by 106,052 shares, bringing its total to 244,814 shares valued at around $2.6 million.
Elicio Therapeutics, Inc. Stock Up 51.1%
Shares of Elicio Therapeutics (NasdaqCM: ELTX) are currently priced at $14.85. The company, with a market cap of about $283 million, is not yet profitable, reflected by its lack of a meaningful P/E ratio. Over the past 52 weeks, the stock has ranged from $7.37 to $16.00. It has a 50-day moving average of $11.37 and a 200-day moving average of $10.07. The company's financial health is supported by a current ratio of 2.24 and a quick ratio of 2.07.
Insider Buying and Selling at Elicio Therapeutics, Inc.
Several insiders at Elicio Therapeutics have recently acquired shares. On February 2, 2026, CEO Robert Connelly purchased 147,200 shares. Other executives, including Christopher Haqq, Peter Demuth, and Preetam Shah, also bought shares on the same day, with Demuth acquiring a total of 41,600 shares.
Analysts Set New Price Targets
On June 10, 2026, B. Riley Securities reiterated its buy rating for Elicio Therapeutics with a $27 price target. Earlier, on April 15, 2026, Ladenburg Thalmann initiated coverage with a buy rating and a $20 target. HC Wainwright & Co. maintained its buy rating on March 13, 2026, with a target of $17. The consensus among analysts is a strong buy, with an average target price of approximately $20.67 based on three opinions.
About Elicio Therapeutics
Elicio Therapeutics, Inc. is a biotechnology company based in Boston, Massachusetts. It focuses on developing immunotherapies for cancer treatment. The company's lead product, ELI-002, is in Phase II trials targeting Kirsten rat sarcoma viral oncogene homolog mutations. Elicio is also working on treatments for BRAF-driven cancers and mutated p53-expressing cancers. Led by CEO Robert T. Connelly, the company employs 33 people.
Bottom Line
B. Riley Securities' reiterated buy rating and $27 target for Elicio Therapeutics underscores confidence in the company's future. Investors and analysts alike are closely watching Elicio's progress in developing cancer immunotherapies. Remember, analyst ratings are one of many tools investors use to make informed decisions.
Get Elicio Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $ELTX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.